Stem Cells Expert Witnesses

Biomedical Engineering, Sports Medicine - Medical device, Biologics, Manufacturing, Risk Management, Design History File, FMEA, Stem Cells, Biomaterials, Product Liability, Intellectual Property, Implant, Collagen, Device testing, Design Controls, Product labeling, CDMO, Quality/Regulatory, Allograft, Forensic Science, Accident Recon

Qualified Nuclear Engineering Officer in the US Navy First author for 3 peer-reviewed original scientific research articles 10+ years in medical device/biologics design, development, and manufacture 15 years in design and operational engineering Inventor on two biomedical patents

Pain Management - Medicine, Physical Medicine & Rehab - Interventional, Chronic Pain, Spinal Cord Stimulator, SCS, DRG, PNS, Pain Pump, Epidural, Radiofrequency, PRP, Stem Cells, Complex Regional Pain Syndrome, CRPS, Nerve Injury, Post-Operative Pain, Work Injury, Opioids, Buprenorphine, Medical Marijuana, Causation, Impairment

Dr. Jacobs is board certified in Pain Medicine, Physical Medicine and Rehabilitation, and Occupational Medicine. He served over 20 years as a Navy physician, including roles as director of Pain Medicine at Walter Reed National Military Medical Center and specialty consultant to the Navy Surgeon General and White House. He now practices as an Interventional Pain Management physician and is an associate professor of anesthesiology at Georgetown University School of Medicine. Dr. Jacobs has served on the guidelines committee of the American Society of Regional Anesthesia and Pain Medicine, published numerous articles, and lectured at national conferences. Dr. Jacobs has an active clinical practice, including the management of complex chronic pain conditions, such as failed back surgery syndrome (post-laminectomy syndrome), complex regional pain syndrome (CRPS), post-surgical pain (e.g hernia, joint replacement, nerve injury), and chronic joint, neck, and back pain. He performs advance...

Biomedical Engineering, Gastroenterology - Diabetes, Obesity, Inflammatory bowel disease, IBD, Stem cells, Bariatric surgery, Microfluidics, Drug screening, Biotechnology, Organoids

I am an Associate Professor at Harvard Medical School, Massachusetts General Hospital, and Shriners Hospital. I received my Ph.D. in Biomedical Engineering and have a well-established record of research in several research areas, including stem cells, gastroenterology, and metabolism (diabetes and obesity). My laboratory's research has been published in leading scientific journals such as Science, Nature Medicine, and Gastroenterology. I also have a successful track record of funding from both federal agencies (such as NIH) and private organizations (including small and large biotech and biopharma companies). I have also frequently served as a consultant for various companies.

Regenerative Medicine, Biomedical Engineering - Regenerative Medicine, Cellular Therapies, Stem Cells, Extracellular Matrix, Perinatal Tissues (Placenta, Amnion, Chorion, Umbilical Cord Blood/Tissue), Transplantation, Cellular & Tissue Engineering, Biotechnology, Bioengineering, Medical Devices, Tissue Processing/Banking, HSCs, MSCs

Dr. Rouzbeh R. Taghizadeh has dedicated more than 20 years to bringing stem cell-based therapies to clinical practice. His expertise in adult stem cells, primarily human hematopoietic and mesenchymal stem cells—the regenerative cells involved in successful bone marrow and umbilical cord blood transplantations—uniquely positions him to approach science and business with the same keen powers of insight that have consistently reaped success surmounting scientific and medical barriers in the field. He earned his Ph.D. in Stem Cell Bioengineering in 2006 from the Massachusetts Institute of Technology (MIT) and co-founded AuxoCell Laboratories, Inc. as Chief Scientific Officer in 2008 after completing his post-doctoral training from MIT and the Boston Biomedical Research Institute. At MIT, in the laboratory of Dr. James L. Sherley, Dr. Taghizadeh focused on developing novel technologies to preferentially expand human hematopoietic stem cells ex vivo, a long-standing challenge faced by b...

Regenerative Medicine - cell therapy, gene therapy, stem cell therapy, immunotherapy, regulatory, FDA, due diligence, HCT/P, Good Manufacturing Practices (GMPs), Good Tissue Practices (GTPs), viral vectors, T cells, CAR-T cells, NK cells, stem cells, autologous cell therapy, allogeneic cell therapy

Dr. Burger has 30 years of experience developing cell therapy and gene therapy products for immunotherapy and regenerative medicine. Since 2002 he has been a full-time consultant on development, GMP manufacturing, regulatory, and strategic aspects of cell and gene therapy. He has served over 180 companies, from biotech startups to Big Pharma, in North America, Europe, Asia, and Australia, consulting on cell and gene therapies from preclinical development through Phase I/II/III, and commercialization. Dr. Burger has been an expert witness in cases involving cell and gene therapy intellectual property, commercialization, FDA regulatory affairs, and GMP compliance. He is frequently an invited speaker at international conferences and has served on the USP Cell, Gene and Tissue Therapies Expert Committee, the ISCT advisory board and ISCT committees on gene therapy, regulatory affairs, commercialization, and product/process development. A graduate of the University of Pennsylvania Sc...